Date: 2017-03-27
Type of information: Nomination
Compound: chief executive officer
Company: Alexion Pharmaceuticals (USA - CT)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: 
• On March 27, 2017, Alexion Pharmaceuticals announced that its Board of Directors has appointed Ludwig N. Hantson , as Chief Executive Officer and member of the Board of Directors, effective immediately. Dr. Hantson most recently served as President and CEO of Baxalta, a spin-off from Baxter, and a global leader in the development of therapies for orphan and underserved diseases in hematology, immunology and oncology. Prior to Baxalta, Dr. Hantson was President of Baxter BioScience, a $6 billion global business unit of Baxter where he drove significant value into its pipeline by adding 25 New Molecular Entities and Biologics License Applications, and launching 13 new products. Dr. Hantson brings to Alexion a strong record of developing diverse rare disease pipelines and commercializing innovative and life-transformative therapies at industry-leading companies.
Prior to his roles at Baxalta and Baxter BioScience, Dr. Hantson held several leadership roles during his decade-long tenure at Novartis from 2001-2010, including CEO of Novartis Pharma North America , CEO of Novartis Europe, and President of Novartis Pharma Canada . He began his career at Smith & Nephew and subsequently served in increasing roles of responsibility in marketing, and research and development at Johnson & Johnson from 1988-2001. Dr. Hantson received his Ph.D. in motor rehabilitation and physical therapy, Master's degree in physical education, and a certification in high secondary education, all from the University of Louvain in Belgium .
He succeeds David R. Brennan , who has led the company as Interim CEO since December 2016 . Mr. Brennan will remain on the Board of Directors and, as the company previously announced, the Board expects to appoint Mr. Brennan as Chairman at the Annual Meeting of Shareholders scheduled for May 10 .
Financial terms:
Latest news:
